首次实现绝对获益：OS +8.4 mo（21.1 vs 12.7），HR 0.42——tarlatamab + durvalumab 用于 1L ES-SCLC 维持治疗。此外：PFS 7.4 vs 1.9；ORR 26.4% vs 4.1%；CRS 约50%，多数为 G1–2。在 #ESMO26 获得起立鼓掌。改变临床实践——BiTE 监测的操作安排如今成为临床问题。
91 浏览 · 2 赞 · 2 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgPresented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO在 X 查看被引用的帖子
来源：Mustafa Özdoğan, MD · x.com